Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 331-338

  Kimer, Nina ^a   Krag, Aleksander ^b   Gluud, Lise L ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Lactulose; Liver cirrhosis; Prevention

Indexed keywords

AMMONIA; LACTULOSE; PLACEBO; RIFAXIMIN;

ARTICLE; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84898849732     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S41565     Document Type: Article

References (60)

1. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675-1682.
2. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52(3):737-741.
3. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25 Suppl 1:3-9.
4. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3): 716-721.
5. Cordoba J. New assessment of hepatic encephalopathy. J Hepatol. 2011;54(5):1030-1040.
6. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33(7):739-747.
7. Mardini H, Record C. Pathogenesis of hepatic encephalopathy: lessons from nitrogen challenges in man. Metab Brain Dis. 2013;28(2): 201-207.
8. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31(5):537-547.
9. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7(9): 515-525.
10. Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med. 2010;362(12):1140-1142.
11. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70(9):1131-1148.
12. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005; 51 Suppl 1:36-66.
13. Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PloS One. 2013;8(4):e60042.
14. Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011;140(2):478-487. e471.
15. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
16. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13(2):109-118.
17. De Marco F, Santamaria Amato P, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res. 1984;36(4):668-674.
18. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38(1):51-58.
19. Parini PCA, Ronchi M, Salzetta A, Mazella G, Roda E. Effect of rifaximin and paromycin in the treatment of portal-systemic encephalopathy. Curr Ther Res. 1992;52(1):34-39.
20. PharmacyChecker [homepage on the Internet]. Available from: http://www.pharmacychecker.com/compare-drug-prices-online-pharmacies/rifaximin-550+mg/79995/197553/. Accessed February 1, 2014.
21. Neff G. Pharmacoeconomics of hepatic encephalopathy. Pharmacotherapy. 2010;30(5 Pt 2):28S-32S.
22. Di Piazza S, Gabriella Filippazzo M, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol. 1991;23(7):403-407.
23. Eftimiadi C, Deleo C, Schito GC. Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res. 1984;10:691-696.
24. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42(5): 674-679.
25. Song KH LK, Kim MH, Paik YH, et al. The clinical efficacy of rifaximin in the treatment of hepatic encephalopathy (comparison with lactulose). Hepatology. 2000;32(4):407A.
26. Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res. 1985;11(6): 387-392.
27. Venturini I, Ferrieri A, Farina F, et al. Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. Drugs Exp Clin Res. 2005;31(4):161-168.
28. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol. 2000;12(2):203-208.
29. Bass NM, Ahmed A, Johnson L, Gardner JD. Rifaximin treatment is beneficial for mild hepatic encephalopathy. Hepatology. 2004;40:646A (abstract).
30. Fera GFA, Nigro M, Schiraldi O, Ferrieri A. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res. 1993;4:57-66.
31. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res. 1993;54(5):598-609.
32. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol. 2003;49(1):53-62.
33. Massa PVF, Dodero M. Treatment of hepatic encephalopathy with rifaximin. Eur J Clin Res. 1993;4:7-18.
34. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin. 1997;13(10): 593-601.
35. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46(3):399-407.
36. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol. 1991;23(4):175-178.
37. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458-1463.
38. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011;106(2):307-316.
39. Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34(8):853-861.
40. Irima R, Trifan A. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hospitalizations in cirrhosis. Rev Med Chir Soc Med Nat Iasi. 2012;116(4):1021-1027.
41. Tandon P, Delisle A, Topal JE, Garcia-Tsao G. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol. 2012;10(11):1291-1298.
42. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28(3):450-455.
43. Bajaj JBE, Paterson C, Forbes WP. Long-term use of rifaximin is associated with reduced hospitalizations, prolonged remission: a placebo crossover analysis. Hepatology. 2012;56(Suppl 4):925A-926A.
44. O'Leary JG, Reddy KR, Wong F, et al. Long-term antibiotic and proton-pump inhibitor use are strong predictors of recurrent infections in cirrhosis: a prospective multi-center study from NACSELD. J Hepatol. 2013;58(Suppl 1):S97.
45. Sanyal AMK, Bass NM, Frederick T, et al. Rates of commonly occurring infections in cirrhosis patients remain stable during long-term rifaximin treatment. J Hepatol. 2012;56(Suppl 1):S255-S256.
46. Mantry PS, Munsaf S. Rifaximin for the treatment of hepatic encephalopathy. Transplant Proc. 2010;42(10):4543-4547.
47. Neff GW, Jones M, Broda T, et al. Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol. 2012;46(2):168-171.
48. Neff GW, Jones M, Jonas M, et al. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. J Clin Gastroenterol. 2013;47(2):188-192.
49. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38(10):3552-3555.
50. Neff GW. Assessing treatment patterns in patients with overt hepatic encephalopathy. Hepatology. 2012;56(Suppl 4):945A.
51. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology. 2012;55(4):1164-1171.
52. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy-a decision analysis. Aliment Pharmacol Ther. 2007;26(8):1147-1161.
53. Neff GW, Kemmer N, Duncan C, Alsina A. Update on the management of cirrhosis-focus on cost-effective preventative strategies. Clinicoecon Outcomes Res. 2013;5:143-152.
54. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885-891, 891. e1.
55. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther. 2010;31(9):1012-1017.
56. Neff G. Factors affecting compliance and persistence with treatment for hepatic encephalopathy. Pharmacotherapy. 2010;30(5 Pt 2): 22S-27S.
57. Chemistdirect. co. uk [homepage on the Internet]. Lactulose solution. Oldbury, UK: Chemist Direct. Available from: http://www.chemistdirect.co.uk/lactulose-solution_1_10158.html#10158. Accessed January 9, 2014.
58. Drugs. com [homepage on the Internet]. Xifaxan. Available from: http://www.drugs.com/xifaxan.html. Accessed January 9, 2014.
59. Prakash RK, Kanna S, Mullen KD. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. Clin Ther. 2013;35(9):1458-1473.
60. Gluud LL, Dam G, Borre M, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis. 2013;28(2):221-225.